Menu

All PLOS Submissions to Appear on bioRxiv

Papers sent to PLOS journals will be automatically uploaded to the preprint server before acceptance.

Feb 9, 2018
Kerry Grens

ISTOCK, LARGEFIELDSTUDIOSAuthors who submit a manuscript to any of the PLOS journals will have their work automatically posted to the preprint site bioRxiv, both publishers announced this week (February 6). Researchers have the option to decline the preprint.

“This collaboration highlights PLOS’s commitment to the growing preprint movement in the biological sciences and bioRxiv’s support for scientists’ desire to share their research freely and widely,” Louise Page, Chief Innovation Officer at PLOS, says in a statement. “The screened submissions to bioRxiv from PLOS illustrate how publishers can drive preprints and create new outputs in response to researcher-led initiatives that increase transparency and promote early dissemination of science.”

PLOS’s screening procedure includes looking for plagiarism and ensuring the research meets ethical standards. Peer reviewers will be able to include comments posted to bioRxiv by readers in their assessments of the submissions.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.